Thrombosis

• 

  Subject Areas on Research

  • "Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis on sepsis-induced coagulopathy in the management of sepsis": reply. 
  • 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. 
  • 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. 
  • 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. 
  • A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. 
  • A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. 
  • A clinical cardiology perspective of thrombophilias. 
  • A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes. 
  • A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. 
  • A comparsion of polyurethane and silastic artificial hearts in 10 long survival experiments in calves. 
  • A directional distance aided method for medical image segmentation. 
  • A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release. 
  • A large-scale study of the upper arm basilic transposition for hemodialysis. 
  • A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation. 
  • A national study of the complications of lupus in pregnancy. 
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 
  • A painful swollen arm in a young woman. 
  • A population-based analysis on the use of therapeutic plasma exchange and intravenous immunoglobulin in heparin-induced thrombocytopenia. 
  • A previously unreported complication of apicoaortic conduit for severe aortic stenosis. 
  • A prospective evaluation of surgically treated groin complications following percutaneous cardiac procedures. 
  • A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. 
  • A quality improvement program for hemodialysis vascular access. 
  • A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 
  • A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. 
  • A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A tale of two centrifugal left ventricular assist devices. 
  • A time-tested ex vivo model of thrombosis: from pathophysiology to drug development and disease application. 
  • ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. 
  • Abdominal aortic aneurysm morphology: CT features in patients with ruptured and nonruptured aneurysms. 
  • Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. 
  • Acardius anceps with evidence of intrauterine vascular occlusion: report of a case and discussion of the pathogenesis. 
  • Accelerated TPA for treatment of prosthetic valve thrombosis. 
  • Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. 
  • Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy. 
  • Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid. 
  • Acute thrombosis of a composite ascending aortic conduit containing a Bjork-Shiley valve during pregnancy: successful emergency cesarean section and operative repair. 
  • Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Age and dose sensitivities in the 2-butoxyethanol F344 rat model of hemolytic anemia and disseminated thrombosis. 
  • Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. 
  • Algorithm for the diagnosis and management of suspected pump thrombus. 
  • Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. 
  • An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 
  • Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. 
  • Angiographic morphology in unstable angina pectoris. 
  • Angiojet rheolytic thrombectomy in infants following cardiac surgery. 
  • Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. 
  • Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. 
  • Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. 
  • Antibodies to topical bovine thrombin correlate with access thrombosis. 
  • Anticardiolipin antibodies and osteonecrosis of the femoral head. 
  • Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 
  • Anticoagulation Strategies in the Perioperative Period for Lung Transplant. 
  • Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. 
  • Anticoagulation for coexisting bioprosthetic aortic valve thrombosis and anticoagulant-related bleeding: "A double edge sword". 
  • Anticoagulation in adult patients supported with extracorporeal membrane oxygenation: guidance from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. 
  • Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. 
  • Anticoagulation: choosing the optimal anticoagulant. 
  • Anticoagulation: indications and risk classification schemes. 
  • Anticoagulation: managing adverse events in patients receiving anticoagulation and perioperative care. 
  • Anticoagulation: monitoring of patients receiving anticoagulation. 
  • Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor. 
  • Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. 
  • Antiphospholipid antibodies in pediatric lupus nephritis. 
  • Antiphospholipid antibody syndrome: current concepts. 
  • Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. 
  • Antiplatelet resistance--fact or myth? 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antiplatelet therapy and platelet function testing. Introduction. 
  • Antiplatelet therapy in pediatric cardiovascular patients. 
  • Antithrombin deficiency in special clinical syndromes--Part II: cardiovascular surgery. 
  • Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. 
  • Antithrombotic Strategies and Device Thrombosis. 
  • Antithrombotic Therapy After Peripheral Vascular Intervention. 
  • Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). 
  • Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses. 
  • Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Antithrombotic therapy after prosthetic cardiac valve implantation: improving postoperative, long-term patient management. Introduction. 
  • Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go? 
  • Antithrombotic therapy: new areas to understand efficacy and bleeding. 
  • Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). 
  • Aortic Valve Thrombus in a Patient With an Extracorporeal Left Ventricular Assist Device: The Dilemma of Management. 
  • Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. 
  • Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. 
  • Arterial reconstruction for radial artery occlusion. 
  • Arterial thrombosis and second cancer in MPNs. 
  • Arteriovenous Graft Delamination and Dissection as a Cause of Graft Dysfunction. 
  • Aspirin and reproductive outcomes. 
  • Aspirin resistance: position paper of the Working Group on Aspirin Resistance. 
  • Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. 
  • Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. 
  • Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. 
  • Assessment of the 2006 revised antiphospholipid syndrome classification criteria. 
  • Assessments of thrombogenicity by three in vitro techniques. Student Research Award in the Undergraduate, Master Candidate, or Health Science Degree Candidate Category, 21st annual meeting of the Society for Biomaterials, San Francisco, CA, March 18-22, 1995. 
  • Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults. 
  • Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. 
  • Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. 
  • Association between thrombosis and bloodstream infection in neonates with peripherally inserted catheters. 
  • Association of weight gain with coronary artery disease, inflammation and thrombogenicity. 
  • Atherothrombosis at a distance: contributing role of existing large-burden vascular disease, circulating biosignals and modulating extravascular tissues. 
  • Atherothrombotic disorders: new insights from hematology. 
  • Atypical aortic thrombus: should nonoperative management be first line? 
  • Autopsy findings with permanent pervenous pacemakers. 
  • Autopsy validation study of the academic research consortium stent thrombosis definition. 
  • Beyond thrombosis: the versatile platelet in critical illness. 
  • Biliary reconstructive techniques and associated anatomic variants in adult living donor liver transplantations: The adult-to-adult living donor liver transplantation cohort study experience. 
  • Biosignatures in thrombotic disorders. 
  • Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. 
  • Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. 
  • Bleeding and thrombosis associated with ventricular assist device therapy. 
  • Bleeding and thrombotic complications of pediatric liver transplant. 
  • Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. 
  • Blocking the initiation of coagulation by RNA aptamers to factor VIIa. 
  • Blood coagulation: hemostasis and thrombin regulation. 
  • Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. 
  • Bone density changes in women who receive thromboprophylaxis in pregnancy. 
  • Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. 
  • Buyer beware: The risks of donor-derived vaccine-induced thrombosis and thrombocytopenia. 
  • COVID-19 Thrombotic Complications and Therapeutic Strategies. 
  • COVID-19 and its implications for thrombosis and anticoagulation. 
  • COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. 
  • Calcified intrahepatic portal vein thrombus: distinction from intrahepatic choledocholithiasis. 
  • Can the US examination for lower extremity deep venous thrombosis be abbreviated? A prospective study of 755 examinations. 
  • Cangrelor for the treatment of patients with Arterial Thrombosis. 
  • Cardiac marker testing: where should we focus? 
  • Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). 
  • Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. 
  • Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021. 
  • Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician's view. 
  • Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations. 
  • Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 
  • Cell-based models of coagulation: a paradigm in evolution. 
  • Central aortic pulse pressure, thrombogenicity and cardiovascular risk. 
  • Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. 
  • Central venous catheters are associated with thrombosis among adult inpatients undergoing therapeutic plasma exchange. 
  • Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study. 
  • Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease. 
  • Challenges for providing effective hemostasis in surgery and trauma. 
  • Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management. 
  • Characteristics of strokes associated with centrifugal flow left ventricular assist devices. 
  • Characterization of a novel prothrombin variant, Prothrombin C20209T, as a modifier of thrombotic risk among African-Americans. 
  • Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. 
  • Classification and treatment of endothermal heat-induced thrombosis: Recommendations from the American Venous Forum and the Society for Vascular Surgery This Practice Guidelines document has been co-published in Phlebology [DOI: 10.1177/0268355520953759] and Journal of Vascular Surgery: Venous and Lymphatic Disorders [DOI: 10.1016/j.jvsv.2020.06.008]. The publications are identical except for minor stylistic and spelling differences in keeping with each journal's style. The contribution has been published under a Attribution-Non Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0), (https://creativecommons.org/licenses/by-nc-nd/4.0/). 
  • Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. 
  • Clinical Valve Thrombosis After Valve-in-Valve Transcatheter Aortic Valve Replacement. 
  • Clinical and imaging predictors of the natural course of bland portal vein thrombus in cirrhotic patients. 
  • Clinical causes and treatment of the thrombotic storm. 
  • Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. 
  • Clinical end points in coronary stent trials: a case for standardized definitions. 
  • Clinical implications for patients on antithrombotic therapy while taking supplements. 
  • Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparin-induced thrombocytopenia. 
  • Clinical practice. Heparin-induced thrombocytopenia. 
  • Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. 
  • Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. 
  • Clopidogrel in infants with systemic-to-pulmonary-artery shunts. 
  • Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. 
  • Clopidogrel: the future choice for preventing platelet activation during coronary stenting? 
  • Coagulation Abnormalities and Clinical Complications in Children With SARS-CoV-2: A Systematic Review of 48,322 Patients. 
  • Coagulation abnormalities and thrombosis in patients with COVID-19. 
  • Coagulation disorders and their cutaneous presentations: Pathophysiology. 
  • Coagulation-induced resistance to fluid flow in small-diameter vascular grafts and graft mimics measured by purging pressure. 
  • Coagulopathy in COVID-19. 
  • Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection? 
  • Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. 
  • Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. 
  • Combination antithrombotic therapies. 
  • Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model. 
  • Communication from the Scientific Standardization Committees of the International Society on Thrombosis and Haemostasis on vascular endothelium-related biomarkers in disseminated intravascular coagulation. 
  • Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis. 
  • Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. 
  • Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog. 
  • Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery. 
  • Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. 
  • Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. 
  • Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. 
  • Complications associated with indwelling catheters. 
  • Complications of implantable venous access devices in patients with sickle cell disease. 
  • Computed tomography angiogram for left ventricular assist device thrombosis: When does it help? 
  • Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. 
  • Contraceptive Management for Women Who Are at High Risk of Thrombosis. 
  • Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. 
  • Contribution of Cardiac Implantable Electronic Devices to Thrombus Formation in Patients With Chronic Thromboembolic Pulmonary Hypertension. 
  • Controversies and Challenges of Ventricular Assist Device Therapy. 
  • Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. 
  • Coughing up blood: Behçet's disease. 
  • Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor? 
  • Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. 
  • Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. 
  • Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. 
  • Dealing with the highs and lows of contrast agents in left main disease. 
  • Defective release of vascular plasminogen activator in patients with gynecologic malignancies. 
  • Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. 
  • Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access. 
  • Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. 
  • Detection of left ventricular thrombi by computerised tomography. A preliminary report. 
  • Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. 
  • Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. 
  • Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. 
  • Development and validation of a predictive model for chemotherapy-associated thrombosis. 
  • Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. 
  • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 
  • Device-Related Thrombus After Left Atrial Appendage Occlusion: The Villain of the Piece. 
  • Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome. 
  • Differential mechanisms of failure of autogenous and non-autogenous bypass conduits: an assessment following successful graft thrombolysis. 
  • Differential platelet levels affect response to taxane-based therapy in ovarian cancer. 
  • Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenia purpura. 
  • Digital ischemia associated with a thrombosed aneurysm of the dorsal interosseous artery. A case report. 
  • Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019? 
  • Direct oral anticoagulants versus vitamin K antagonists in the first 3 months after bioprosthetic valve replacement: a systematic review and meta-analysis. 
  • Direct thrombin inhibitors. 
  • Direct thrombin inhibitors: alternatives to heparin. 
  • Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. 
  • Disseminated thrombosis in primary antiphospholipid syndrome: MR findings. 
  • Do anticoagulation with heparin and protamine reversal alter thrombogenicity of coated and noncoated pulmonary artery catheters? 
  • Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. 
  • Does this patient have a severe upper gastrointestinal bleed? 
  • Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. 
  • Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. 
  • Drug-eluting stents "deliver heartburn": how do we spell relief going forward? 
  • Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. 
  • Drugs for percutaneous coronary interventions. 
  • Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). 
  • Dual-Energy Multidetector Computed Tomography With Iodine Quantification in the Evaluation of Portal Vein Thrombosis: Is It Possible to Discard the Unenhanced Phase? 
  • Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. 
  • Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • Early intervention for lactate dehydrogenase elevation improves clinical outcomes in patients with the HeartMate II left ventricular assist device: Insights from the PREVENT study. 
  • Early operative intervention after thrombolytic therapy for primary subclavian vein thrombosis: an effective treatment approach. 
  • Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. 
  • Early versus delayed, provisional eptifibatide in acute coronary syndromes. 
  • Early-onset obesity and the unwanted promise of thrombosis. 
  • Echocardiographic Algorithm for Post-Myocardial Infarction LV Thrombus: A Gatekeeper for Thrombus Evaluation by Delayed Enhancement CMR. 
  • Echocardiography allows safer venous cannulation during excision of large right atrial masses. 
  • Editor's page: fundamentals in neurocardiology: the brain-platelet-coronary artery interface. 
  • Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation. 
  • Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial. 
  • Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. 
  • Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 
  • Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial. 
  • Effect of dipyridamole plus aspirin on hemodialysis graft patency. 
  • Effect of home testing of international normalized ratio on clinical events. 
  • Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots. 
  • Effect of mild hypothermia on the thrombolytic efficacy of 120 kHz ultrasound enhanced thrombolysis in an in-vitro human clot model. 
  • Effect of multielement intravascular ultrasound on the anticoagulant potency of enoxaparin. 
  • Effectiveness of homocysteine lowering vitamins in prevention of thrombotic tendency at high altitude area: A randomized field trial. 
  • Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. 
  • Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries. 
  • Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. 
  • Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. 
  • Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. 
  • Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. 
  • Elimination of predilection sites for thrombus formation in the total artificial heart--before and after. 
  • Embolic stroke from mural thrombi, a fatal complication of axillary artery catheterization. 
  • Embolization of cardiac mural thrombus: complication of intraarterial fibrinolysis. 
  • Emergence of factor IXa as a target for pharmacologic inhibition: editors page. 
  • Emergencies after liver transplantation. 
  • Emerging paradigms in arterial thrombosis. 
  • Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. 
  • Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. 
  • Epidurals in patients receiving thromboprophylaxis with unfractionated heparin three times a day: the value of activated partial thromboplastin time testing. 
  • Ether lipid metabolism by AADACL1 regulates platelet function and thrombosis. 
  • Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. 
  • Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. 
  • Evaluation of effect of scheduled fresh frozen plasma on ECMO circuit life: A randomized pilot trial. 
  • Evaluation of left atrial appendage anatomy and function in recent-onset atrial fibrillation by transesophageal echocardiography. 
  • Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. 
  • Evaluation of the thrombogenecity of microvascular prosthesis by in vivo microscopy. 
  • Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. 
  • Exercise and atherosclerotic heart disease in women. 
  • Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. 
  • Extracorporeal Membrane Oxygenation for Hemodynamic Support. 
  • Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. 
  • Factor Xa-A pleuripotential protease. 
  • Factor Xa-protease activated receptor interface: a paradigm for combination pharmacotherapy. 
  • Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. 
  • Fatal Thrombosis After Factor VII Administration During Extracorporeal Membrane Oxygenation. 
  • Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. 
  • Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). 
  • Feasibility of laser-targeted photoocclusion of the choriocapillary layer in rats. 
  • Femoral artery pseudoaneurysms: value of color Doppler sonography in predicting which ones will thrombose without treatment. 
  • Fetal renal vein thrombosis, hydrops fetalis, and maternal lupus anticoagulant. A case report. 
  • Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation. 
  • Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. 
  • Focus on thrombosis : Applying management guidelines in clinical practice. 
  • Foreword: The Prevention and Management of Thrombosis in Obstetrics and Gynecology. 
  • Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. 
  • G-protein-coupled receptors signaling pathways in new antiplatelet drug development. 
  • Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. 
  • Genitourinary case of the day. Angiomyolipoma of the kidney with fat thrombus in the inferior vena cava. 
  • Genome sequencing unveils a regulatory landscape of platelet reactivity. 
  • Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. 
  • Glutathione peroxidase-3 deficiency promotes platelet-dependent thrombosis in vivo. 
  • Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. 
  • Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. 
  • Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. 
  • Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study. 
  • Heartmate III Replacement for Recurring Left Ventricular Assist Device Pump Thrombosis. 
  • Hematologic and surgical management of the dental patient with plasminogen activator deficiency. 
  • Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. 
  • Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. 
  • Hemorrhage and thrombus formation in early experimental osteonecrosis. 
  • Hemostasis and thrombosis in older adults. 
  • Hemostasis: old system, new players, new directions. 
  • Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis. 
  • Heparin coating of vascular prostheses reduces thromboemboli. 
  • Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. 
  • Heparin-Induced Thrombocytopenia: A Focus on Thrombosis. 
  • Heparin-induced thrombocytopenia and thrombosis. 
  • Heparin-induced thrombocytopenia, a prothrombotic disease. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. 
  • High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. 
  • Higher Body Mass Index Increases Risk of HeartMate II Pump Thrombosis But Does Not Adversely Affect Long-Term Survival. 
  • Highlights from the 46 th annual meeting of the American Society of Hematology. 
  • Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil. 
  • Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil. 
  • Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. 
  • Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. 
  • Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil. 
  • Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. 
  • Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. 
  • Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. 
  • Hormonal contraception and thrombotic risk: a multidisciplinary approach. 
  • How I approach hereditary hemolytic anemia and splenectomy. 
  • How I treat catastrophic thrombotic syndromes. 
  • How to manage coagulopathies in critically ill patients. 
  • Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis. 
  • Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. 
  • Hydrostatic pressure reduces thrombogenicity of polytetrafluoroethylene vascular grafts. 
  • Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. 
  • Hypercoagulable states in cardiovascular disease. 
  • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. 
  • Idarucizumab for Dabigatran Reversal. 
  • Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. 
  • Identifying Sex Dimorphism in Peripheral Artery Disease with Platelet Mapping. 
  • Iloprost in alginate decreases the thrombogenicity of expanded polytetrafluoroethylene. 
  • Image-Guided Percutaneous Gastrostomy Tube Placement is Safe in Patients Requiring Aspirin 325 mg. 
  • Images in cardiovascular medicine. Noninvasive characterization of left atrial mass. 
  • Immunity to thrombotic events is achievable if we stop the guessing game: is this the major hidden message from GRAVITAS? 
  • Immunothrombotic Activity of Damage-Associated Molecular Patterns and Extracellular Vesicles in Secondary Organ Failure Induced by Trauma and Sterile Insults. 
  • Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 
  • Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. 
  • Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry. 
  • Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. 
  • Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention. 
  • Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand. 
  • Improved microsurgical anastomotic patency with low molecular weight heparin. 
  • In Vitro Evidence for the Role of Cytokine Storm in the Generation of Stent Thrombosis in COVID-19 Patients. 
  • In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets. 
  • In vivo performance of dual ligand augmented endothelialized expanded polytetrafluoroethylene vascular grafts. 
  • In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
  • In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. 
  • Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. 
  • Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. 
  • Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). 
  • Inferior myocardial infarction complicated by mural thrombus and systemic embolization despite anticoagulation in progressive systemic sclerosis with normal coronary arteriograms. 
  • Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. 
  • Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists. 
  • Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. 
  • Inhibition of intimal hyperplasia by direct thrombin inhibitors in an animal vein bypass model. 
  • Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. 
  • Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus. 
  • Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. 
  • International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. 
  • International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. 
  • Intimal tears and their relationship to long-term patency in the rat femoral artery. 
  • Intracardiac thrombus formation during orthotopic liver transplantation: a new entity or an old enemy? 
  • Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. 
  • Intravascular thrombosis in skeletal muscle microcirculation after ischemia. 
  • Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. 
  • Introducers and protective sleeves may increase thrombogenicity of pulmonary artery catheters. 
  • Inverted left atrial appendage appearing as a left atrial mass with transesophageal echocardiography during cardiac surgery. 
  • Is streptokinase safe during menses? 
  • Is thrombogenesis related to residual platelet function in ischaemic heart disease? 
  • Ischemia/reperfusion injury in microvascular surgery. 
  • Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. 
  • Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. 
  • JCL Roundtable: Global Think Tank on Lipoprotein(a). 
  • LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR. 
  • LVAD Outflow Graft Role in Pump Thrombosis. 
  • LW protein: a promiscuous integrin receptor activated by adrenergic signaling. 
  • Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. 
  • Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). 
  • Left Atrial Appendage Closure: Two Steps Forward, One Step Back. 
  • Left Atrial Appendage Thrombus and Embolic Stroke. 
  • Left ventricular endocardial irregularity: evaluation using epicardial echocardiography. 
  • Links between the immune and coagulation systems: how do "antiphospholipid antibodies" cause thrombosis? 
  • Lipids and stroke: a paradox resolved. 
  • Liver transplantation. 
  • Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. 
  • Long-Term Embolic Outcomes After Detection of Left Ventricular Thrombus by Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Imaging: A Matched Cohort Study. 
  • Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. 
  • Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. 
  • Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. 
  • Loss of the cytoskeletal protein Pdlim7 predisposes mice to heart defects and hemostatic dysfunction. 
  • Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial. 
  • Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial. 
  • Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. 
  • Lymph node infarction: role of underlying malignancy, tumour proliferation fraction and vascular compromise--a study of 35 cases and a comprehensive review of the literature. 
  • Major complications associated with transcatheter atrial septal occluder implantation: a review of the medical literature and the manufacturer and user facility device experience (MAUDE) database. 
  • Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis. 
  • Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). 
  • Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). 
  • Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. 
  • Managing Heavy Menstrual Bleeding in Women at Risk of Thrombosis. 
  • Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. 
  • Mechanical Thrombectomy of Acutely Occluded Flow Diverters. 
  • Mechanical versus chemical thrombolysis: an in vitro differentiation of thrombolytic mechanisms. 
  • Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. 
  • Mesenteric vein thrombosis and vascular plasminogen activator. 
  • Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. 
  • Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. 
  • Microparticles from aged packed red blood cell units stimulate pulmonary microthrombus formation via P-selectin. 
  • Mixed connective tissue disease with arterial thrombosis, antiphospholipid antibodies and heparin induced thrombocytopenia. 
  • Model predictions of deformation, embolization and permeability of partially obstructive blood clots under variable shear flow. 
  • Modelling the linkage between influenza infection and cardiovascular events via thrombosis. 
  • Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. 
  • Modulating atherothrombosis: is there a place for vaccines in global prevention strategies? 
  • Modulation of ultralarge immune complexes in heparin-induced thrombocytopenia. 
  • Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling. 
  • Multicenter evaluation of the bovine mesenteric vein bioprostheses for hemodialysis access in patients with an earlier failed prosthetic graft. 
  • Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE). 
  • Multidisciplinary care of the pregnant patient with or at risk for venous thromboembolism: a recommended toolkit from the Foundation for Women and Girls with Blood Disorders Thrombosis Subcommittee. 
  • Multiplane transesophageal echocardiographic assessment of left atrial appendage anatomy and function. 
  • NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. 
  • Natural History of Iatrogenic Pediatric Femoral Artery Injury. 
  • Neutrophil accumulation and NET release contribute to thrombosis in HIT. 
  • Nitric oxide-producing polyurethanes. 
  • Nonsurgical management of obstructive aortic thrombosis complicated by renovascular hypertension in the neonate. 
  • Novel constructs for thrombin inhibition. 
  • Novel intravenous antithrombins. 
  • Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. 
  • Nucleic acid scavengers inhibit thrombosis without increasing bleeding. 
  • Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. 
  • Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVID-19 in the US. 
  • Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease. 
  • One-year cardiovascular event rates in outpatients with atherothrombosis. 
  • Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. 
  • Outcome after splenic vein thrombosis in the pancreas allograft. 
  • Outcomes associated with ablation compared to combined ablation and transilluminated powered phlebectomy in the treatment of venous varicosities. 
  • Outcomes associated with peripherally inserted central catheters in hospitalised children: a retrospective 7-year single-centre experience. 
  • Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. 
  • PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. 
  • PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. 
  • PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. 
  • PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. 
  • Paecilomyces varioti endocarditis on a prosthetic aortic valve. 
  • Pannus-related prosthetic valve dysfunction and life-threatening aortic regurgitation. 
  • Paradoxical embolus following percutaneous thrombectomy of hemodialysis reliable outflow graft. 
  • Paraprosthetic-duodenal fistula involving a mesocaval shunt. 
  • Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. 
  • Patent foramen ovale and intracardiac thrombus identified by transesophageal echocardiography during liver transplantation. 
  • Pathobiology of atherosclerosis and plaque complications. 
  • Pathogenesis of heparin-induced thrombocytopenia and thrombosis. 
  • Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. 
  • Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial. 
  • Patient-specific antithrombotic strategies: lessons not yet learned from the renal insufficiency paradigm. 
  • Percutaneous Thrombectomy in Patients with Occlusions of the Aortoiliac Segment: A Case Series. 
  • Percutaneous transhepatic recanalization and thrombolysis of the superior mesenteric vein. 
  • Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH. 
  • Perioperative Management of the Gynecologic Patient on Long-term Anticoagulation. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Peripheral vascular complications during transcatheter aortic valve replacement: management and potential role of chronic steroid use. 
  • Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. 
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 
  • Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. 
  • Pharmacoeconomics and the formulary decision-making process. 
  • Pharmacogenetics of Clopidogrel: An Unresolved Issue. 
  • Photodynamic retinal vascular thrombosis. Rate and duration of vascular occlusion. 
  • Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. 
  • Platelet Activation and Thrombosis in COVID-19. 
  • Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. 
  • Platelet PlA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. 
  • Platelet activation and its patient-specific consequences. 
  • Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. 
  • Platelet function and pharmacologic inhibition. 
  • Platelet reactivity and thrombogenicity in postmenopausal women. 
  • Platelets from genome to proteome and beyond. 
  • Platelets in atherothrombosis. 
  • Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. 
  • Pneumatic compression or aspirin prophylaxis against thromboembolism in total hip arthroplasty. 
  • Point-of-Care Rapid-Seeding Ventricular Assist Device with Blood-Derived Endothelial Cells to Create a Living Antithrombotic Coating. 
  • Point-of-care platelet function analysis ready for prime time? 
  • Polyphosphazenes: effect of molecular motions on thrombogenesis. 
  • Portosystemic shunts in children: a 15-year experience. 
  • Posey palsy. 
  • Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Postintervention Patency Rates and Predictors of Patency after Percutaneous Interventions on Intragraft Stenoses within Failing Prosthetic Arteriovenous Grafts. 
  • Postoperative management. 
  • Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. 
  • Prasugrel: Clinical development and therapeutic application. 
  • Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. 
  • Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. 
  • Predictive value of access blood flow in detecting access thrombosis. 
  • Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). 
  • Pregnancy and thrombotic risk. 
  • Pregnancy-associated thrombosis. 
  • Prenatal screening for thrombophilia: the background and the approach. 
  • Preoperative Platelet Count Predicts Lower Extremity Free Flap Thrombosis: A Multi-Institutional Experience. 
  • Preoperative anemia predicts thrombosis and free flap failure in microvascular reconstruction. 
  • Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery. 
  • Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. 
  • Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. 
  • Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. 
  • Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. 
  • Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. 
  • Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses. 
  • Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. 
  • Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021): From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care (SFAR). 
  • Primary endovascular therapy with clot retrieval and balloon angioplasty for acute basilar artery occlusion. 
  • Primary upper-extremity deep venous thrombosis. 
  • Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. 
  • Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention. 
  • Prognostic significance of microvascular thrombosis in donor kidney allograft biopsies. 
  • Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. 
  • Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. 
  • Prosthetic valve thrombosis: when and how should we lyse? 
  • Protein S deficiency: imaging findings. 
  • Proteomic Analysis of Infants Undergoing Cardiopulmonary Bypass Using Contemporary Ontological Tools. 
  • Pseudoaneurysms at aortic cannulation site after coronary artery bypass graft: MR findings. 
  • Pulmonary arterial hypertension and myeloproliferative disorders. 
  • Pulmonary artery thrombus in a premature neonate treated with recombinant tissue plasminogen activator. 
  • Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry. 
  • Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry. 
  • Quantification of gas denucleation and thrombogenicity of vascular grafts. 
  • Quantification of in vitro endothelial cell adhesion to vascular graft material. 
  • REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. 
  • Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. 
  • Radiation exposure and coronary atherothrombosis. 
  • Radiation hand exposure during restoration of flow to the thrombosed dialysis access graft. 
  • Ramping up evidence-based ventricular assist device care. 
  • Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). 
  • Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. 
  • Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. 
  • Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. 
  • Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. 
  • Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. 
  • Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. 
  • Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. 
  • Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. 
  • Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. 
  • Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. 
  • Recognizing the risk of postpartum thrombosis among obese women and planning accordingly. 
  • Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. 
  • Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. 
  • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. 
  • Reducing the risk of hemodialysis access. 
  • Reducing the risk of oral contraceptive-induced thrombosis. 
  • Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. 
  • Regional anesthesia for vascular access surgery. 
  • Regulatable aptamers in medicine: focus on antithrombotic strategies. 
  • Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. 
  • Relation of Activated Clotting Times During Percutaneous Coronary Intervention to Outcomes. 
  • Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. 
  • Releasable vascular plasminogen activator and thrombotic strokes. 
  • Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis. 
  • Remedial operations for failed endovascular therapy of 32 renal artery stenoses in 24 children. 
  • Renal sympathetic denervation and ventricular arrhythmias: a case of electrical storm with multiple renal arteries. 
  • Rescue thrombolysis: resolution of intraglomerular thrombi after donation after circulatory death. 
  • Resistance to antiplatelet drugs: current status and future research. 
  • Resistance to antiplatelet drugs: what progress has been made? 
  • Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. 
  • Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". 
  • Results of the FUEL Trial. 
  • Review of the biology of bleeding and clotting in the surgical patient. 
  • Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. 
  • Risk factors for peripherally inserted central venous catheter complications in children. 
  • Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. 
  • Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII). 
  • Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. 
  • Routine postprocedure ultrasound increases rate of detection of femoral arterial thrombosis in infants after cardiac catheterization. 
  • Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. 
  • Safety and Efficacy of Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Second-Generation Drug-Eluting Stents in Real-World Practice. 
  • Safety of recombinant activated factor VII in randomized clinical trials. 
  • Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study. 
  • Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial. 
  • Safety profile of recombinant factor VIIa. 
  • Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: the roles of medial and luminal factors in arterial healing. 
  • Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. 
  • Serial assessment of thrombogenicity and hemodynamics in patients with type II diabetes in a clinical research unit: Evidence for circadian variations in clot formation. 
  • Signaling via P2Y12 may be critical for early stabilization of platelet aggregates. 
  • Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. 
  • Single-Cell Analysis Reveals Distinct Immune and Smooth Muscle Cell Populations that Contribute to Chronic Thromboembolic Pulmonary Hypertension. 
  • Six-month follow-up after thermal balloon angioplasty in canine iliac arteries. 
  • Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). 
  • Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. 
  • Spontaneous bilateral renal pelvis thrombus formation presenting as anuric acute renal failure. 
  • Spontaneous retrocarpal radial artery thrombosis: a report of two cases. 
  • Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. 
  • Strong Binding of Platelet Integrin αIIbβ3 to Fibrin Clots: Potential Target to Destabilize Thrombi. 
  • Stuck Between a Clot and a Cold Place: The Specter of Early In-Stent Thrombosis With Therapeutic Hypothermia. 
  • Successful Management of Catastrophic Thrombotic Storm in a Young Boy: A Case Report From Northern India. 
  • Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. 
  • Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. 
  • Surveillance of fistula function by frequent recirculation measurements during high efficiency dialysis. 
  • Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. 
  • Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings. 
  • TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care. 
  • Targeting patients undergoing angioplasty for thrombus inhibition: a cost-effectiveness and decision support model. 
  • Teaching NeuroImages: Artery of Percheron thrombosis causing selective downgaze palsy. 
  • Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. 
  • Techniques and applications of perioperative therapeutic plasma exchange. 
  • Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. 
  • The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. 
  • The Axillary Intra-Aortic Balloon Pump as a Bridge to Recovery Allows Early Ambulation in Long-Term Use: Case Series and Literature Review. 
  • The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. 
  • The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. 
  • The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. 
  • The Judicious Use of Recombinant Factor VIIa. 
  • The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. 
  • The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. 
  • The U.S. Thrombosis and Hemostasis Centers pilot sites program. 
  • The balance of thrombosis and hemorrhage in surgery. 
  • The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II. 
  • The case of the disappearing myxoma. 
  • The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study. 
  • The coagulation cascade in cirrhosis. 
  • The coagulopathy, endotheliopathy, and vasculitis of COVID-19. 
  • The complications of brachial arteriotomy. 
  • The difference between clopidogrel responsiveness and posttreatment platelet reactivity. 
  • The effect of exposure time on microsurgical anastomoses of experimentally crushed arteries. 
  • The effect of heparin after microsurgical repair in traumatically damaged arteries. 
  • The effect of interstitial air on the in vitro thrombogenicity of ePTFE vascular grafts. 
  • The effect of rate of heating or cooling prior to heating on tumor and normal tissue microcirculatory blood flow. 
  • The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. 
  • The evolution of platelet-directed pharmacotherapy. 
  • The fibula-flexor hallucis longus osteomuscular flap. 
  • The hemodynamics of thrombus formation in arteries. 
  • The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. 
  • The impact of femoral arterial thrombosis in paediatric cardiac catheterisation: a national study. 
  • The importance of factor Xa regulatory pathways in vascular thromboresistance: focus on protein Z. 
  • The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. 
  • The many faces of the contact pathway and their role in thrombosis. 
  • The multiple roles of tissue factor in wound healing. 
  • The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? 
  • The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. 
  • The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. 
  • The process of bringing new drug-eluting stents to market will they see the light of day? 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. 
  • The role of cardiac MR in new-onset heart failure. 
  • The role of microparticles in inflammation and thrombosis. 
  • The role of neutrophils in thrombosis. 
  • The role of prasugrel in the management of acute coronary syndromes: a systematic review. 
  • The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. 
  • The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. 
  • The scientific basis for evaluation and management of thrombotic disorders. 
  • The utility of cone beam volume CT in the evaluation of thrombosed intracranial aneurysms in subarachnoid hemorrhage. 
  • The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 
  • Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. 
  • Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. 
  • Thoracic imaging features of patients with antiphospholipid antibodies. 
  • Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. 
  • Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. 
  • Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. 
  • Thrombin: science and application in clinical practice. 
  • Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy. 
  • Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. 
  • Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history. 
  • Thrombogenesis: effect of molecular motions, surface order, and hydrophobicity of the polymer interface. 
  • Thrombolytic therapy for arterial thrombosis. 
  • Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. 
  • Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. 
  • Thrombosed polytetrafluoroethylene hemodialysis fistulas: salvage with combined thrombectomy and angioplasty. 
  • Thrombosed synthetic hemodialysis access fistulas: the success of combined thrombectomy and angioplasty (technical note). 
  • Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. 
  • Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding. 
  • Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. 
  • Thrombosis and thrombolysis in crushed arteries with or without anastomosis: a new microvascular thrombosis model. 
  • Thrombosis during pregnancy and the postpartum period. 
  • Thrombosis in acute promyelocytic leukemia. 
  • Thrombosis in infants in the neonatal intensive care unit: Analysis of a large national database. 
  • Thrombosis in pregnancy and maternal outcomes. 
  • Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. 
  • Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: analysis of 8,517 patients. 
  • Thrombotic microangiopathy in anti-glomerular basement membrane glomerulonephritis. 
  • Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. 
  • Thrombotic, infectious, and procedural complications of the jugular bulb catheter in the intensive care unit. 
  • Thrombus around the redesigned HeartWare HVAD inflow cannula: A pathologic case series. 
  • Thrombus imaging with indium-111 platelets. 
  • Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. 
  • Thrombus on the inflow cannula of the HeartWare HVAD: an update. 
  • Thrombus-trapping efficiency of the Greenfield filter in vivo. 
  • Ticagrelor for the treatment of arterial thrombosis. 
  • Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. 
  • Tissue factor, thrombin, and cancer. 
  • Transcatheter electrocoagulation: experimental evaluation of the anode. 
  • Transesophageal Echocardiographic Observation of Caval Thrombus Followed by Intraoperative Placement of Inferior Vena Cava Filter for Presumed Pulmonary Embolism During Cesarean Hysterectomy for Placenta Percreta: A Case Report. 
  • Transesophageal assessment of left atrial thrombus using a 3.3-mm monoplane probe. 
  • Transesophageal echocardiography and noncardiac surgery: how far does the nondiagnostic use go? 
  • Transesophageal echocardiography versus oral anticoagulation before electrical cardioversion of atrial fibrillation: what about atrial clot size? 
  • Transesophageal echocardiography-guided aortic thrombectomy in a patient with a mobile thoracic aortic thrombus. 
  • Transient Bacteremia Promotes Catheter-Related Central Venous Thrombosis through Neutrophil Extracellular Traps. 
  • Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. 
  • Translation and Clinical Development of Antithrombotic Aptamers. 
  • Transplant-Free Survival and Interventions at 6 Years in the SVR Trial. 
  • Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide. 
  • Treatment of thrombosed hemorrhoids by excision. 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥65 Years (from the CathPCI Registry). 
  • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. 
  • Two urokinase dose regimens in native arterial and graft occlusions: initial results of a prospective, randomized clinical trial. 
  • Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. 
  • UNUSUAL NEUROLOGICAL AND CARDIOVASCULAR COMPLICATIONS OF RESPIRATORY FAILURE. 
  • Ulnar artery insufficiency: a guide to treatment. 
  • Ulnar artery thrombosis. 
  • Ulnar artery thrombosis: a sports-related injury. 
  • Ultrasound accelerated catheter directed thrombolysis for pulmonary embolus and right heart thrombus secondary to transvenous pacing wires. 
  • Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. 
  • Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. 
  • Unexpected abrupt increase in left ventricular assist device thrombosis. 
  • Unilateral pulmonary venous occlusion caused by a localized pericardial clot. 
  • Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade. 
  • Unusual cause of superior vena cava syndrome diagnosed with transesophageal echocardiography. 
  • Urologic complications in renal transplantation. 
  • Urologic morbidity in renal transplantation. 
  • Use of aspirin associates with longer primary patency of hemodialysis grafts. 
  • Use of autologous blood-derived endothelial progenitor cells at point-of-care to protect against implant thrombosis in a large animal model. 
  • Use of transoesophageal echocardiography to detect left atrial thrombi before percutaneous balloon dilatation of the mitral valve: a prospective study. 
  • Usefulness and Cost-Effectiveness of Universal Echocardiographic Contrast to Detect Left Ventricular Thrombus in Patients with Heart Failure and Reduced Ejection Fraction. 
  • Uses of antithrombin III concentrate in congenital and acquired deficiency states. 
  • Utilization of Thromboelastography with Platelet Mapping to Predict Infection and Poor Wound Healing in Postoperative Vascular Patients. 
  • VEGF inhibition and renal thrombotic microangiopathy. 
  • VEGF inhibition and renal thrombotic microangiopathy. 
  • Validated model of platelet slip at stenosis and device surfaces. 
  • Validation of the dual radiotracer method for quantitative In-111 platelet scintigraphy. 
  • Variability of antiplatelet response in patients with peripheral artery disease. 
  • Variants in chondroitin sulfate metabolism genes in thrombotic storm. 
  • Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry. 
  • Vascular artifact mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in abdominal vascular assessment. 
  • Vascular diseases and MR angiography of the liver. 
  • Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic. 
  • Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. 
  • Vorapaxar in the secondary prevention of atherothrombosis. 
  • Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device. 
  • Warfarin in antiphospholipid syndrome--time to explore new horizons. 
  • Warfarin in vulnerable older adults with atrial fibrillation. 
  • Watchman implantation in a patient with left atrial appendage thrombus. 
  • We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity. 
  • What Do We Really Know About Pulmonary Thrombosis in COVID-19 Infection? 
  • What does it take to make the perfect clot? 
  • When i do a TEE, am I ready for what comes next? 
  • Why coat a stent with polymer? 
  • Why is lipoprotein(a) relevant to thrombosis? 
  • [Hematologic diseases: from within the heart]. 
  • [Predictive value of the GRACE discharge score on the long-term out-of-hospital coronary thrombotic events after implantation of drug-eluting stents]. 
  • eComment. Mural thrombus in normal appearing aorta: Unfinished saga in uncharted waters. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Ghadimi, Kamrouz, Associate Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Hoffman, Maureane, Professor of Pathology, Integrative Immunobiology
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics